

At page 48, line 11, please delete "its U.S. designation".

At page 48, line 12, please replace "XX/XXX,XXX" with 09/____,____, "Methods of

Q10

Producing Anti-Angiogenic Proteins", by Vikas P. Sukhatme, filed June 7, 2000--.

At page 59, line 14, please replace "PCD" with --programmed cell death (PCD)--.

REMARKS

Remarks on the Amendments Under Article 34 PCT

The changes submitted under Article 34 of the PCT were made to correct obvious typographical and grammatical errors and to supply SEQ ID NOs, with some exceptions. These included changes made to (1) insert the PCT serial numbers of other PCT applications referred to in the specification (pages 15, 17, 27 and 51 of PCT/US98/26057); (2) reflect subdivision of originally-filed Fig. 26A-B into Figs. 26A, 26B and 26C (page 8 of PCT/US98/26057); (3) replace by text strings several hypothetical sequences that had been provided for illustrative purposes (page 20 of PCT/US98/26057); (4) correct an inadvertent reference to plasminogen instead of endostatin (page 37 of PCT/US98/26057), which correction would have been obvious to one of ordinary skill; (5) correct (on page 21 of PCT/US98/26057) an example of a conservative substitution, which correction would have been obvious to one of ordinary skill in the art; (6) correct SEQ ID NO:4 (on page 48 of PCT/US98/26057), which correction is supported by the correct presentation of this sequence in the table on pages 10-11 of PCT/US98/26057; (7) correct SEQ ID NOs:8 and 9 (on page 50 of PCT/US98/26057), which corrections are supported by the correct presentation of these sequences in the table on pages 10-11 of PCT/US98/26057; and (9) add the complete citations of references that were either submitted or in press at the time of filing of PCT/US98/26057, where one of ordinary skill could have looked up the citations in MedLine after publication (page 17 of PCT/US98/26057). Claims 1 and 2 were amended to correct grammatical errors. Claims 10 and 14 were amended to correct a lack of antecedent basis.

Remarks on the Amendments Presented Herein

Applicant also respectfully requests entry of the amendments presented above. The majority of these amendments are made in regard to two other PCT applications which were incorporated by reference, and their "U.S. designation" applications. These applications are being filed as continuation applications rather than U.S. National Phase applications, and so

Applicant has presented amendments to these passages that accurately reflect the type of application. Serial numbers and filing dates will be inserted by amendment in a second Preliminary Amendment to be filed at a future date.

Applicant has also amended SEQ ID NO:16. This amendment is supported by the correct presentation of this primer on page 5 ("upstream primer") and Fig. 6 of U.S.S.N. 60/067,888, from which the present application claims priority, and which is incorporated by reference in its entirety in the present application.

Applicant has also amended SEQ ID NO:21. This amendment is supported by the correct presentation of this primer on page 4 of U.S.S.N. 60.108,536, from which the present application claims priority, and which is incorporated by reference in its entirety in the present application.


Applicant also submits herewith revised Figs. 26B and 26C, which contain the above amendments to SEQ ID NO:16 and SEQ ID NO:21.

Applicant also respectfully submits herewith a Sequence Listing which reflects these amendments to SEQ ID NO:16 and SEQ ID NO:21.

Applicant's agent hereby states that the content of the continuation application presented herewith and co-pending application PCT/US98/26057 are the same and that the continuation application includes no new matter.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 

Joyce C. Hersh
Registration No. 42,890
Telephone (781) 861-6240
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: 